Holen Sie sich die Stockscreener-App
26.85
6.36%
-1.99
Handel nachbörslich:
26.70
-0.15
-0.56%
Avalyn Pharma Inc Aktie (AVLN) Neueste Nachrichten
This Lear Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday - Benzinga
Evercore Initiates AVALYN PHARMA INC(AVLN.US) With Buy Rating, Announces Target Price $51 - Moomoo
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Jefferies Initiates Avalyn Pharma at Buy With $52 Price Target - Moomoo
Morgan Stanley Initiates AVALYN PHARMA INC(AVLN.US) With Buy Rating, Announces Target Price $53 - Moomoo
Morgan Stanley initiates Avalyn Pharma stock coverage with overweight rating - Investing.com Australia
Guggenheim initiates Avalyn Pharma stock with buy rating on fibrosis drugs By Investing.com - Investing.com Australia
Jefferies initiates Avalyn Pharma stock with buy on lung disease data - Investing.com
Guggenheim initiates Avalyn Pharma stock with buy rating on fibrosis drugs - Investing.com Australia
Jefferies Initiates AVALYN PHARMA INC(AVLN.US) With Buy Rating, Announces Target Price $52 - Moomoo
Avalyn Pharma Inc. (AVLN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
AVLN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AVLN Technical Analysis | Trend, Signals & Chart Patterns | AVALYN PHARMA INC (NASDAQ:AVLN) - ChartMill
Avalyn Pharma to present 4-year AP01 data at EULAR conference By Investing.com - Investing.com South Africa
Avalyn Pharma to present 4-year AP01 data at EULAR conference - Investing.com
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026 - The Manila Times
4 years on inhaled pirfenidone for lung scarring at EULAR 2026 - Stock Titan
IPO Tracker 2026: Parabilis follows hefty Regeneron deal with IPO push - BioSpace
Top Avalyn Pharma (AVLN) Competitors 2026 - MarketBeat
AVLN SEC FilingsAVALYN PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
AVLN News | AVALYN PHARMA INC (NASDAQ:AVLN) - ChartMill
Number of shareholders of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Avalyn Pharma prices $300M IPO at $18 per share - MSN
Suvretta funds build Avalyn Pharma (AVLN) stake via IPO and open-market buys - Stock Titan
SR One funds disclose 3.31M-share Avalyn Pharma (AVLN) position after IPO - Stock Titan
What is the current Price Target and Forecast for Avalyn Pharma Inc. (AVLN) - Zacks Investment Research
Avalyn Pharma (AVLN) Stock Trends and Sentiment 2026 - MarketBeat
Avalyn Pharma (AVLN) Stock Analysis Report | Financials & Insights - Benzinga
Perceptive group discloses 6.0% stake in Avalyn Pharma (NASDAQ: AVLN) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Avalyn brings patient feedback on lung fibrosis care to ATS 2026 - Stock Titan
Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference - The Manila Times
Lung disease drug developer Avalyn surges on public debut - MSN
Novo Holdings (NASDAQ: AVLN) buys shares and converts preferred into Avalyn common - Stock Titan
Avalyn Pharma Insider Bought Shares Worth $5,000,004, According to a Recent SEC Filing - Moomoo
Avalyn Pharma Inc. (AVLN) - Minichart
Preferred dividends of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
After tax other income/expense of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Cash per share of Avalyn Pharma Inc. – BOATS:AVLN - TradingView
Number of employees of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
AVLN PE Ratio & Valuation, Is AVLN Overvalued - Intellectia AI
Avalyn Pharma completes $345 million IPO on nasdaq - Investing.com India
AVLN Price Today: Avalyn Pharma Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Avalyn Pharma completes $345 million IPO on nasdaq By Investing.com - Investing.com Canada
Avalyn Pharma (AVLN) 10K Form and Latest SEC Filings 2026 - MarketBeat
IPO NewsUS IPO Weekly Recap: Biotech, early-stage mining, and Bill Ackman close out the April IPO market - renaissancecapital.com
Finance Watch: Avalyn, Hemab And Seaport Launch $856m Worth Of IPOs - Citeline News & Insights
Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Avalyn Pharma closes $345 million IPO on Nasdaq By Investing.com - Investing.com Australia
Avalyn Pharma Inc. Completes Successful Initial Public Offering Raising $345 Million - Moomoo
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):